GIP receptor antagonist and GLP-1 receptor agonist
Maridebart cafraglutide 280 mg injection every 4 weeks
MARI_SC_280MG_Q4W
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.62 (0.01 to 41.64) | 0.59 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.71 (0.01 to 57.12) | 0.64 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.44 (0.61 to 12.85) | 0.62 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 11.88 (2.60 to 77.64) | 0.20 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.25 (0.23 to 25.68) | 0.45 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.59 (0.08 to 28.53) | 0.54 |